PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...

This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to a prostate cancer ...

SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Nicholas Kavoussi discussing artificial ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...

(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of localized radiorecurrent prostate cancer, and a presentation by Dr. Behfar ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...

Radical cystectomy (RC) is a morbid operation with a high rate of perioperative complications. If patients survive their cancer, long-term complications significantly impact their quality of life. Dr.

(UroToday.com) The 2024 SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Eric Jonasch discussing a phase 1B/2 study of combination 177 Lu Girentuximab + ...

ADT (including second generation agents), pelvic nodal radiotherapy, hydrogel placement, and boosting dominant nodules were allowed per investigator discretion. The results demonstrated that ...

SUO annual meeting included a prostate cancer session, featuring a presentation by medical student Nishan Sohoni discussing the classification of adverse events after prostate cancer hydrogel ...